Ribbon Bio GmbH announced today the commercial launch of MiroSynth™ DNA, a breakthrough product designed to meet the increasing demand for complex, highly accurate synthetic DNA molecules. The Vienna-based DNA synthesis company unveiled its first commercial offering at the Global Synthetic Biology Conference in San Jose, California, running from May 5-8, 2025.
MiroSynth™ DNA leverages Ribbon Bio's proprietary algorithm-driven technology and precision enzymatic assembly process to produce synthetic DNA with exceptional accuracy and performance. The platform aims to overcome long-standing limitations in DNA synthesis and assembly, potentially transforming scientific possibilities across multiple fields.
"This is a defining milestone for Ribbon Bio as we commercialize synthetic DNA at the highest levels of complexity and accuracy," said Jodi Barrientos, CEO of Ribbon Bio. "MiroSynth™ DNA offers unmatched quality for researchers developing next-generation solutions in therapeutics, life sciences, and beyond. We're proud to serve scientists who are pushing the boundaries of possibility today."
Advanced Technology Platform
The MiroSynth™ platform represents a significant advancement in synthetic DNA production, combining intelligent algorithms with enzymatic assembly techniques. This approach enables the creation of longer, more complex DNA molecules with higher accuracy than conventional methods.
Available in both linear and circular formats, MiroSynth™ DNA is specifically engineered to address the growing need for complex and highly accurate DNA at length. The product name itself—inspired by the Latin word for "extraordinary"—reflects its potential to transform scientific research by overcoming traditional limitations in DNA synthesis.
Market Availability and Applications
Researchers and organizations across the United States, European Union, United Kingdom, and Australia can now access MiroSynth™ DNA to accelerate their scientific work. The initial target markets include biopharma, life sciences, and academic research, where complex DNA constructs are essential for advancing new therapeutic approaches and fundamental research.
The technology's ability to produce pristine synthetic DNA molecules with high accuracy and unprecedented speed could enable partners to develop transformative solutions for human health and environmental applications.
Conference Presentations
As part of the product launch, Ribbon Bio is sponsoring the Global Synthetic Biology Conference 2025 and participating in two featured sessions on May 6:
CEO Jodi Barrientos will host a Spotlight Session highlighting Ribbon's end-to-end DNA synthesis platform, focusing on the integration of intelligent algorithms, enzymatic assembly, adaptive automation, and full traceability from sequence to molecule.
CTO Dr. John Luckey will join a panel discussion exploring how complex synthetic DNA is reshaping the future of science and innovation.
Industry Impact
The introduction of MiroSynth™ DNA comes at a critical time when synthetic biology is rapidly expanding into new application areas. Advanced DNA synthesis capabilities are increasingly essential for developing novel therapeutics, engineered biological systems, and research tools.
By providing researchers with access to more complex and accurate DNA constructs, Ribbon Bio aims to accelerate scientific breakthroughs across multiple disciplines. The company's technology could potentially address bottlenecks in the development pipeline for gene therapies, synthetic vaccines, and other advanced biological products.
Ribbon Bio describes itself as a synthetic biology leader "making the impossible possible" through its algorithm-driven technology that produces synthetic DNA molecules with high accuracy and speed. The company's mission focuses on enabling partners to deliver transformative solutions for human health and environmental challenges.
